Skip to main content
SpringerLink
Log in

Schizophrenia: The drug deadlock

  • News Feature
  • Published:

From Nature

View current issue Submit your manuscript

The biology is too complicated. Pharma companies are quitting. Where are schizophrenia drugs going to come from?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lieberman, J. A. et al. N. Engl. J. Med. 353, 1209-1223 (2005).

    Article  CAS  Google Scholar 

  2. Buchanan, R. W. et al. Schizophr. Bull. 31, 5-19 (2005).

    Article  Google Scholar 

  3. Kirkpatrick, B., Fenton, W. S., Carpenter, W. T. Jr & Marder, S. R. Schizophr. Bull. 32, 214-219 (2006).

    Article  Google Scholar 

  4. Steffanson, H. et al. Nature 455, 232-236 (2008).

    Article  ADS  Google Scholar 

Download references

Authors
  1. Alison Abbott
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Schizophrenia special

Neuropsychiatric disease Insight

Related external links

NewMeds initiative

MATRICS initiative

CATIE initiative

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abbott, A. Schizophrenia: The drug deadlock. Nature 468, 158–159 (2010). https://doi.org/10.1038/468158a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/468158a

  • Springer Nature Limited

This article is cited by

Search

Navigation